Hunter Syndrome Clinical Trials

34 clinical trials for Hunter Syndrome across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• AN OPEN-LABEL EXTENSION FOR SUBJECTS IN STUDIES HGT-HIT-046 AND SHP609-302 EVALUATING LONG-TERM SAFETY OF INTRATHECAL IDURSULFASE-IT ADMINISTERED IN CONJUNCTION WITH INTRAVENOUS ELAPRASE® IN SUBJECTS WITH HUNTER SYNDROME AND COGNITIVE IMPAIRMENT — RECRUITING
• A PHASE 1/2, MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF DNL310 IN PEDIATRIC SUBJECTS WITH HUNTER SYNDROME — RECRUITING · PHASE1
• "AN OPEN LABEL EXTENSION OF STUDY HGT-HIT-094 EVALUATING LONG TERM SAFETY AND CLINICAL OUTCOMES OF INTRATHECAL IDURSULFASE ADMINISTERED IN CONJUNCTION WITH ELAPRASE IN PATIENTS WITH HUNTER SYNDROME AND COGNITIVE IMPAIRMENT." — RECRUITING
• A CONTROLLED, RANDOMIZED, TWO-ARM, OPEN-LABEL, ASSESSOR-BLINDED, MULTICENTER STUDY OF INTRATHECAL IDURSULFASE-OT ADMINISTERED IN CONJUNCTION WITH ELAPRASE IN PEDIATRIC PATIENTS WITH HUNTER SYNDROME AND EARLY COGNITIVE IMPAIRMENT — RECRUITING
• RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome) — ACTIVE_NOT_RECRUITING · PHASE3
• Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome — OTHER
• Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age — COMPLETED · PHASE4
• A Phase 1/2, Multicenter, Open-Label Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL310 in Pediatric Participants with Hunter Syndrome — OTHER · PHASE2
• An Extension Study to Assess the Long-term Safety and Efficacy of Hunterase (Idursulfase Beta) — COMPLETED · PHASE3
• MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis — ACTIVE_NOT_RECRUITING · PHASE2
• A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II) — WITHDRAWN · PHASE4
• Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment — ACTIVE_NOT_RECRUITING · PHASE2
• An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment — COMPLETED · PHASE1
• Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094 — COMPLETED · PHASE2
• A Study of Elaprase in Children and Adults With Hunter Syndrome (Mucopolysaccharidosis II) in India — COMPLETED · PHASE4
• Hunter Outcome Survey (HOS) — COMPLETED
• A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS Ⅱ — ACTIVE_NOT_RECRUITING · PHASE1
• MPS II Immunophenotyping — TERMINATED
• A Study of GC1111 in Hunter Syndrom Patients — COMPLETED · PHASE3
• Intensive Pharmacovigilance Program for Elaprase (SHP ELA-701) — COMPLETED
• Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders — TERMINATED · PHASE1
• Biomarkers for Hunter Syndrome — TERMINATED
• A PHASE 1/2/3 MULTICENTER, OPEN LABEL STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF RGX-121 IN PEDIATRIC SUBJECTS WITH MPS II (HUNTER SYNDROME) — COMPLETED · PHASE1
• A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase® — COMPLETED · PHASE1
• Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase® — COMPLETED
• Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment — COMPLETED · PHASE2
• Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase — COMPLETED · PHASE2
• Collection and Study of Cerebrospinal Fluid in Patients With Hunter Syndrome — COMPLETED
• An Observational Study Evaluating Anti-Idursulfase Serum Antibody Response in Hunter Syndrome Patients — COMPLETED
• Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy — COMPLETED · PHASE4
• Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients With Hunter Syndrome (MPS II) — COMPLETED
• Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders — COMPLETED · PHASE2
• Safety and Efficacy of Hunterase — COMPLETED · PHASE3
• The Long-term Safety Study of Idursulfase-beta in Hunter Syndrome(Mucopolysaccharidosis II) Patients — OTHER

Refine this search